News

The fact that R-Japan received the license of cell processing facility through the auditing from Pharmaceuticals and Medical Devices Agency (PMDA) on May 18, 2015 two months after

Breckenridge and Alembic filed their Paragraph IV ANDA on the first-to-file date and expect to share 180-day exclusivity with other ANDA first filers. Alembic Pharmaceuticals Limited is the

RHB-104 is an antibiotic combination therapy in oral capsule formulation, with potent intracellular, anti-mycobacterial and anti-inflammatory properties. Currently, RHB-104 is undergoing a first Phase III study for Crohn’s

Jointly developed with Nexgen Pharma, Tuxarin ER will be the first product to provide long lasting cough suppression with a safer opiate that is less prone to respiratory

The NIH grant of $299,585 is for the first year of a two-year project period beginning this July. The grant will be used to support the preclinical testing

The tablet combines Gilead’s emtricitabine 200mg and tenofovir alafenamide (TAF) 25mg with Janssen Sciences Ireland’s rilpivirine 25mg (R/F/TAF). The company said that the data submitted in the NDA

DE-122 is the ophthalmic formulation of Santen’s partner Tracon Pharmaceuticals’ anti-endoglin antibody, TRC105. In March last year, Santen licensed the global rights for the development of TRC105 in

AV-101 is a clinical-stage prodrug candidate that readily gains access to the central nervous system (CNS) after systemic administration and is rapidly converted in vivo to its active

The decision to cease distribution follows a negative outcome of price negotiations with the GKV-Spitzenverband, the German national association of statutory health insurance funds. Tresiba provides an ultra-long